Open-house biologic discount agreements for Denosumab 2025-31
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-31 - Denosumab
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum or estimated quantities are specified; revenue depends on actual market uptake and prescriptions.
Lot 1 (60mg) has been terminated early as of 30.06.2026, so only one lot is now available.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Nov 2027
- Conclusion of rebate agreements for Denosumab (120mg active lot) with health insurance funds
- Open-house procedure: all eligible pharmaceutical entrepreneurs can join on uniform terms
Show full summary
This is an Open-House procedure for Denosumab rebate contracts (Rabattverträge) under §130a Abs. 8 SGB V, organized by Techniker Krankenkasse and other health insurance funds. Originally two lots (60mg and 120mg), but Lot 1 (60mg) was terminated early as of 30.06.2026. Only Lot 2 (120mg) remains active for new participants. The procedure is a continuous open-house: any eligible pharmaceutical entrepreneur can join at any time until the contract end (30.11.2027). No estimated values or award criteria with weights are provided. Eligibility is restricted to pharmaceutical entrepreneurs with a valid marketing authorization for the respective product and who meet reliability criteria. Submission is via email (with qualified electronic signature) or postal mail. The notice explicitly states this is not a public procurement but an open-house arrangement, so procurement law remedies are not applicable; disputes go to social courts.
Risks
No minimum or estimated quantities are specified; revenue depends on actual market uptake and prescriptions.
Lot 1 (60mg) has been terminated early as of 30.06.2026, so only one lot is now available.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG for the offered product
- Valid marketing authorization (Zulassung) for the product according to §21 Abs. 1 AMG
Eligibility
- No conviction or exclusion grounds analogous to §§123, 124 GWB within last 5/3 years
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Denosumab (60mg)
Lot for Denosumab 60mg. This lot has been terminated early as of 30.06.2026. No new participation possible. No estimated value or award criteria provided.
Location
Duration
Category
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Value note
Show original TED data
Original lot title
Denosumab (Wirkstärke 60mg)
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
LOT-0002
Denosumab (120mg)
Lot for Denosumab 120mg. Open-house: continuous participation possible until 30.11.2027. No estimated value or award criteria provided.
Location
Duration
Category
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Value note
Show original TED data
Original lot title
Denosumab (Wirkstärke 120mg)
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab im Rahmen eines Open-House-Verfahrens. Bitte beachten Sie die vorgenommene Losaufteilung des Wirkstoffs.
Procurement Details
- Publication date
- 25 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 356153-2026
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum or estimated quantities are specified; revenue depends on actual market uptake and prescriptions.
Lot 1 (60mg) has been terminated early as of 30.06.2026, so only one lot is now available.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications